Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR
Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended using cystatin C to confirm the diagnosis of chronic kidney disease (CKD) determined by creatinine-based esti...
Uloženo v:
| Vydáno v: | Kidney360 Ročník 3; číslo 10; s. 1807 - 1814 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
American Society of Nephrology
27.10.2022
|
| Témata: | |
| ISSN: | 2641-7650, 2641-7650 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended using cystatin C to confirm the diagnosis of chronic kidney disease (CKD) determined by creatinine-based estimated glomerular filtration rate (eGFR) and to estimate kidney function when accurate eGFR estimates are needed for clinical decision-making. In the efforts to remove race from eGFR calculations in the United States, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Joint Task Force recommended increasing availability and clinical adoption of cystatin C to assess kidney function. This review summarizes the key advantages and limitations of cystatin C use in clinical practice. Our goals were to review and discuss the literature on cystatin C; understand the evidence behind the recommendations for its use as a marker of kidney function to diagnose CKD and risk stratify patients for adverse outcomes; discuss the challenges of its use in clinical practice; and guide clinicians on its interpretation. |
|---|---|
| AbstractList | Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended using cystatin C to confirm the diagnosis of chronic kidney disease (CKD) determined by creatinine-based estimated glomerular filtration rate (eGFR) and to estimate kidney function when accurate eGFR estimates are needed for clinical decision-making. In the efforts to remove race from eGFR calculations in the United States, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Joint Task Force recommended increasing availability and clinical adoption of cystatin C to assess kidney function. This review summarizes the key advantages and limitations of cystatin C use in clinical practice. Our goals were to review and discuss the literature on cystatin C; understand the evidence behind the recommendations for its use as a marker of kidney function to diagnose CKD and risk stratify patients for adverse outcomes; discuss the challenges of its use in clinical practice; and guide clinicians on its interpretation. Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended using cystatin C to confirm the diagnosis of chronic kidney disease (CKD) determined by creatinine-based estimated glomerular filtration rate (eGFR) and to estimate kidney function when accurate eGFR estimates are needed for clinical decision-making. In the efforts to remove race from eGFR calculations in the United States, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Joint Task Force recommended increasing availability and clinical adoption of cystatin C to assess kidney function. This review summarizes the key advantages and limitations of cystatin C use in clinical practice. Our goals were to review and discuss the literature on cystatin C; understand the evidence behind the recommendations for its use as a marker of kidney function to diagnose CKD and risk stratify patients for adverse outcomes; discuss the challenges of its use in clinical practice; and guide clinicians on its interpretation.Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommended using cystatin C to confirm the diagnosis of chronic kidney disease (CKD) determined by creatinine-based estimated glomerular filtration rate (eGFR) and to estimate kidney function when accurate eGFR estimates are needed for clinical decision-making. In the efforts to remove race from eGFR calculations in the United States, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) Joint Task Force recommended increasing availability and clinical adoption of cystatin C to assess kidney function. This review summarizes the key advantages and limitations of cystatin C use in clinical practice. Our goals were to review and discuss the literature on cystatin C; understand the evidence behind the recommendations for its use as a marker of kidney function to diagnose CKD and risk stratify patients for adverse outcomes; discuss the challenges of its use in clinical practice; and guide clinicians on its interpretation. |
| Author | Estrella, Michelle M. Rifkin, Dena Chen, Debbie C. Potok, O. Alison |
| Author_xml | – sequence: 1 givenname: Debbie C. surname: Chen fullname: Chen, Debbie C. organization: Kidney Health Research Collaborative, University of California, San Francisco and San Francisco VA Health Care System, San Francisco, California – sequence: 2 givenname: O. Alison surname: Potok fullname: Potok, O. Alison organization: University of California, San Diego and San Diego VA Health Care System, San Francisco, California – sequence: 3 givenname: Dena surname: Rifkin fullname: Rifkin, Dena organization: University of California, San Diego and San Diego VA Health Care System, San Francisco, California – sequence: 4 givenname: Michelle M. orcidid: 0000-0002-8902-9576 surname: Estrella fullname: Estrella, Michelle M. organization: Kidney Health Research Collaborative, University of California, San Francisco and San Francisco VA Health Care System, San Francisco, California |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36514729$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1UUtrVDEUDlKxtXbtTrJ04bR53ptshHL7sDggiAV3IZN77kw0k9Qk09J_b3SmWoWSRXJyvsfhOy_RXkwREHpNyTEXpOtPPl6dHRNCOCPtsGfogHWCzvpOkr1H7310VMq3hmOaMcW7F2ifd5KKnukD9PV0vLWx2iWUd3ju177a6lNshY0jHoKP3tmAh_blR8jbJvYRXxcfl3i4L78IEQ-4Jnxeql_bCvjy4vMr9HyyocDR7j5E1xfnX4YPs_mny6vhdD5zsg0-65zVCiYttLaCkF7qyYHisBilpXKhhCWaSseZ6BRTilE-9aOTC2eVZFJN_BC93-rebBZrGB3Emm0wN7lNku9Nst7824l-ZZbp1uietnRoE3i7E8jpxwZKNWtfHIRgI6RNMayXQhIhlG7QN4-9_pg8xNkAcgtwOZWSYTJuF2iz9sFQYn5vzrTNmb-ba7yT_3gP0k8z-JZxl0KFXL6HzR1kswIb6upJ1k91xKkV |
| CitedBy_id | crossref_primary_10_2337_dc24_2519 crossref_primary_10_3390_ijms26072869 crossref_primary_10_1186_s12940_024_01135_6 crossref_primary_10_1016_j_talanta_2024_127039 crossref_primary_10_1016_j_lpm_2023_104175 crossref_primary_10_1007_s00467_025_06655_y crossref_primary_10_1016_j_xkme_2025_101068 crossref_primary_10_31083_RCM36643 crossref_primary_10_3390_diagnostics15101225 crossref_primary_10_1002_jcph_70046 crossref_primary_10_1097_LVT_0000000000000439 crossref_primary_10_1155_2023_6648920 crossref_primary_10_1002_adsr_202400042 crossref_primary_10_1002_jac5_70035 crossref_primary_10_1016_j_nurpra_2023_104562 crossref_primary_10_1177_00045632251329182 crossref_primary_10_1016_j_resuscitation_2023_109911 crossref_primary_10_1093_jalm_jfad022 crossref_primary_10_1016_j_mcna_2023_03_011 crossref_primary_10_1002_cpt_3612 crossref_primary_10_2215_CJN_0000000000000225 crossref_primary_10_1093_ndt_gfad113 crossref_primary_10_1016_j_jtho_2024_08_026 crossref_primary_10_1111_1753_0407_13534 crossref_primary_10_1136_bmjonc_2024_000645 crossref_primary_10_1111_jgs_19014 crossref_primary_10_2337_dc23_0261 crossref_primary_10_1016_j_ijantimicag_2025_107586 crossref_primary_10_1093_eurjpc_zwae352 crossref_primary_10_3389_fendo_2024_1434299 crossref_primary_10_1002_ccd_31535 crossref_primary_10_1016_j_jcrc_2023_154450 crossref_primary_10_7759_cureus_73185 crossref_primary_10_3390_geriatrics10040104 crossref_primary_10_1007_s00467_024_06517_z crossref_primary_10_1186_s12014_025_09551_7 crossref_primary_10_3390_ijms25158135 crossref_primary_10_1007_s40262_025_01558_5 crossref_primary_10_1053_j_akdh_2024_07_004 crossref_primary_10_1136_bmj_2022_074216 crossref_primary_10_1007_s11845_025_03874_y crossref_primary_10_1039_D5MO00018A crossref_primary_10_1093_clinchem_hvae226 crossref_primary_10_1016_j_annepidem_2025_04_004 crossref_primary_10_3390_nu15204392 crossref_primary_10_1681_ASN_0000000636 crossref_primary_10_5527_wjn_v14_i3_102756 crossref_primary_10_1002_hsr2_70263 crossref_primary_10_1186_s12882_024_03767_9 crossref_primary_10_1016_j_ekir_2025_04_006 crossref_primary_10_1097_TA_0000000000004401 crossref_primary_10_2337_dci25_0029 crossref_primary_10_1007_s00421_024_05610_3 crossref_primary_10_1016_j_jtho_2023_09_1444 crossref_primary_10_1053_j_ajkd_2025_06_022 crossref_primary_10_1007_s11428_024_01273_y crossref_primary_10_7759_cureus_70413 crossref_primary_10_1080_08037051_2025_2533456 crossref_primary_10_1093_clinchem_hvaf063 crossref_primary_10_1093_ckj_sfad083 crossref_primary_10_1080_00365513_2025_2559354 crossref_primary_10_1038_s41598_023_31048_2 crossref_primary_10_1007_s00467_023_06045_2 crossref_primary_10_3390_bios15010039 crossref_primary_10_3390_jcm14020496 crossref_primary_10_1159_000538854 crossref_primary_10_1016_j_healun_2024_08_010 crossref_primary_10_1186_s12938_024_01295_z crossref_primary_10_1002_phar_70000 crossref_primary_10_1007_s11255_025_04501_6 crossref_primary_10_1080_14740338_2025_2525970 crossref_primary_10_1186_s12882_024_03793_7 crossref_primary_10_1016_j_chroma_2024_464739 crossref_primary_10_1016_j_medcle_2023_12_012 crossref_primary_10_1097_HPC_0000000000000386 crossref_primary_10_1002_jpn3_70188 crossref_primary_10_1002_jcla_25139 crossref_primary_10_1002_jcsm_13551 crossref_primary_10_1016_j_jtct_2024_03_021 |
| Cites_doi | 10.1681/ASN.2010050483 10.1111/j.1523-1755.2004.00517.x 10.1007/BF03347201 10.1038/s41598-018-27672-y 10.1097/TP.0b013e3181744225 10.1053/j.ajkd.2020.05.017 10.5414/CNP62241 10.3109/00365513.2010.546879 10.1681/ASN.2005050545 10.1056/NEJMoa1214234 10.1056/NEJMoa043161 10.1128/AAC.01487-20 10.1016/S1470-2045(10)70275-8 10.1111/j.0954-6820.1985.tb08880.x 10.7326/0003-4819-145-4-200608150-00003 10.1053/j.ajkd.2017.03.021 10.1038/ki.2008.638 10.1053/j.ajkd.2016.07.021 10.1159/000439231 10.3390/pharmacy8010035 10.1186/s12879-020-05246-6 10.1080/00365519950185076 10.1081/JDI-100104727 10.1159/000071287 10.1001/archinte.164.6.659 10.1053/j.ajkd.2020.05.018 10.1371/journal.pone.0243618 10.1681/ASN.2004030203 10.1681/ASN.2005101122 10.1053/j.ajkd.2016.11.016 10.1681/ASN.2020081144 10.1001/jamanetworkopen.2021.48940 10.1001/jama.2011.468 10.1159/000511848 10.1038/ki.2008.67 10.1016/j.clinbiochem.2017.01.005 10.7326/0003-4819-142-7-200504050-00008 10.1056/NEJMoa041031 10.1373/clinchem.2016.264325 10.1056/NEJMoa2102953 10.1124/dmd.112.048918 10.7326/0003-4819-147-1-200707030-00004 10.1038/s41591-019-0627-8 10.1038/ki.2010.431 10.1056/NEJMoa1114248 10.2215/CJN.00690110 10.1038/ki.1990.182 10.1080/00365513.2021.1989714 10.1038/ki.2014.66 10.1310/hct1505-199 10.3109/00365519609088795 10.1681/ASN.2005050512 10.5858/arpa.2014-0427-CP 10.1111/j.1755-6686.2011.00228.x |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 by the American Society of Nephrology Copyright © 2022 by the American Society of Nephrology. Copyright © 2022 by the American Society of Nephrology 2022 |
| Copyright_xml | – notice: Copyright © 2022 by the American Society of Nephrology – notice: Copyright © 2022 by the American Society of Nephrology. – notice: Copyright © 2022 by the American Society of Nephrology 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.34067/KID.0003202022 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2641-7650 |
| EndPage | 1814 |
| ExternalDocumentID | PMC9717651 36514729 10_34067_KID_0003202022 K3602022000320C |
| Genre | review-article Journal Article Review |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: K23 DK128604 |
| GroupedDBID | 0R~ 53G AAAAV AAHPQ AAIQE AASCR AAUIN ABASU ABDIG ABVCZ ABXYN ABZZY ACILI ACLDA ACXJB ACZKN ADGGA ADHPY ADPDF ADSXY AFBFQ AFDTB AFEXH AFNMH AHOMT AHQNM AHQVU AINUH AJCLO AJNWD AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMKUR AMNEI AOHHW AOQMC DIWNM EBS EEVPB ERAAH FCALG GNXGY GQDEL GROUPED_DOAJ HLJTE IKREB M~E OPUJH OVD OVDNE RPM TEORI TSPGW AAYXX ACBKD ADKSD CITATION ACIJW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5032-6ca98ef9499a400759fce83ebd5a15b84a0915c32468288213f7dc5bca85258f3 |
| ISICitedReferencesCount | 99 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000876642000024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2641-7650 |
| IngestDate | Tue Nov 04 02:06:54 EST 2025 Thu Oct 02 10:42:21 EDT 2025 Thu Apr 03 07:00:22 EDT 2025 Sat Nov 29 07:38:35 EST 2025 Tue Nov 18 22:12:23 EST 2025 Mon Aug 25 20:30:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | eGFR cystatin C clinical nephrology |
| Language | English |
| License | Copyright © 2022 by the American Society of Nephrology. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c5032-6ca98ef9499a400759fce83ebd5a15b84a0915c32468288213f7dc5bca85258f3 |
| Notes | Correspondence: Dr. Michelle M. Estrella, 4150 Clement St., Building 2, Room 145, San Francisco, CA 94121. Email: michelle.estrella@ucsf.edu ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-8902-9576 |
| OpenAccessLink | http://dx.doi.org/10.34067/KID.0003202022 |
| PMID | 36514729 |
| PQID | 2754504489 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9717651 proquest_miscellaneous_2754504489 pubmed_primary_36514729 crossref_citationtrail_10_34067_KID_0003202022 crossref_primary_10_34067_KID_0003202022 wolterskluwer_health_10_34067_KID_0003202022 |
| PublicationCentury | 2000 |
| PublicationDate | 20221027 |
| PublicationDateYYYYMMDD | 2022-10-27 |
| PublicationDate_xml | – month: 10 year: 2022 text: 20221027 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Kidney360 |
| PublicationTitleAbbrev | Kidney360 |
| PublicationTitleAlternate | Kidney360 |
| PublicationYear | 2022 |
| Publisher | American Society of Nephrology |
| Publisher_xml | – name: American Society of Nephrology |
| References | Omote, Matsuoka, Arakawa, Nakanishi, Tamai (B45) 2018; 8 Bargnoux, Piéroni, Cristol, Kuster, Delanaye, Carlier, Fellahi, Boutten, Lombard, González-Antuña, Delatour, Cavalier (B27) 2017; 63 Potok, Ix, Shlipak, Katz, Hawfield, Rocco, Ambrosius, Cho, Pajewski, Rastogi, Rifkin (B41) 2020; 76 Chen, Shlipak, Scherzer, Bauer, Potok, Rifkin, Ix, Muiru, Hsu, Estrella (B39) 2022; 5 Inker, Eneanya, Coresh, Tighiouart, Wang, Sang, Crews, Doria, Estrella, Froissart, Grams, Greene, Grubb, Gudnason, Gutiérrez, Kalil, Karger, Mauer, Navis, Nelson, Poggio, Rodby, Rossing, Rule, Selvin, Seegmiller, Shlipak, Torres, Yang, Ballew, Couture, Powe, Levey (B13) 2021; 385 Peralta, Shlipak, Fan, Ordoñez, Lash, Chertow, Go (B20) 2006; 17 Centers for Medicare and Medicaid Services : Local Coverage Determination: Cystatin C Measurement. LCD ID: L37561. Available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=37561&DocType=2. Accessed February 22, 2022 Foster, Levey, Inker, Shafi, Fan, Gudnason, Katz, Mitchell, Okparavero, Palsson, Post, Shlipak (B6) 2017; 70 Inker, Schmid, Tighiouart, Eckfeldt, Feldman, Greene, Kusek, Manzi, Van Lente, Zhang, Coresh, Levey (B12) 2012; 367 Go, Chertow, Fan, McCulloch, Hsu (B14) 2004; 351 Levey (B51) 1990; 38 Shlipak, Katz, Sarnak, Fried, Newman, Stehman-Breen, Seliger, Kestenbaum, Psaty, Tracy, Siscovick (B2) 2006; 145 Peralta, Muntner, Scherzer, Judd, Cushman, Shlipak (B35) 2015; 42 Ku, McCulloch, Adey, Li, Johansen (B52) 2021; 32 Manetti, Pardini, Genovesi, Campomori, Grasso, Morselli, Lupi, Pellegrini, Bartalena, Bogazzi, Martino (B11) 2005; 28 Keith, Nichols, Gullion, Brown, Smith (B21) 2004; 164 Stevens, Schmid, Greene, Li, Beck, Joffe, Froissart, Kusek, Zhang, Coresh, Levey (B5) 2009; 75 Peralta, Katz, Sarnak, Ix, Fried, De Boer, Palmas, Siscovick, Levey, Shlipak (B34) 2011; 22 Grubb, Björk, Nyman, Pollak, Bengzon, Ostner, Lindström (B4) 2011; 71 Sjöström, Tidman, Jones (B47) 2004; 62 Menon, Wang, Sarnak, Hunsicker, Madero, Beck, Collins, Kusek, Levey, Greene (B15) 2008; 73 Sarnak, Katz, Stehman-Breen, Fried, Jenny, Psaty, Newman, Siscovick, Shlipak (B3) 2005; 142 Grubb, Simonsen, Sturfelt, Truedsson, Thysell (B1) 1985; 218 Risch, Blumberg, Huber (B54) 2001; 23 Peralta, Shlipak, Judd, Cushman, McClellan, Zakai, Safford, Zhang, Muntner, Warnock (B18) 2011; 305 Centers for Medicare and Medicaid Services : Clinical Laboratory Fee Schedule Files, file CLAB2022Q1. Available at: https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/22clabq1. Accessed February 22, 2022 Menon, Shlipak, Wang, Coresh, Greene, Stevens, Kusek, Beck, Collins, Levey, Sarnak (B17) 2007; 147 Zhou, Chen, He, Xue (B53) 2022; 82 Galsky, Hahn, Rosenberg, Sonpavde, Hutson, Oh, Dreicer, Vogelzang, Sternberg, Bajorin, Bellmunt (B50) 2011; 12 Karger, Long, Inker, Eckfeldt (B26) Shlipak, Wassel Fyr, Chertow, Harris, Kritchevsky, Tylavsky, Satterfield, Cummings, Newman, Fried (B24) 2006; 17 Tummalapalli, Shlipak, Damster, Jha, Malik, Levin, Johnson, Bello (B25) 2020; 51 Shlipak, Matsushita, Ärnlöv, Inker, Katz, Polkinghorne, Rothenbacher, Sarnak, Astor, Coresh, Levey, Gansevoort (B16) 2013; 369 Liu, Foster, Tighiouart, Anderson, Beck, Contreras, Coresh, Eckfeldt, Feldman, Greene, Hamm, He, Horwitz, Lewis, Ricardo, Shou, Townsend, Weir, Inker, Levey (B7) 2016; 68 Ismail, Bhayana, Kadour, Lepage, Gowrishankar, Filler (B29) 2017; 50 Vinge, Lindergård, Nilsson-Ehle, Grubb (B9) 1999; 59 Frazee, Rule, Lieske, Kashani, Barreto, Virk, Kuper, Dierkhising, Leung (B37) 2017; 69 Tangri, Stevens, Schmid, Zhang, Beck, Greene, Coresh, Levey (B8) 2011; 79 Maillard, Mariat, Bonneau, Mehdi, Thibaudin, Laporte, Alamartine, Chamson, Berthoux (B57) 2008; 85 Yap, Lamarche, Peguero, Courville (B46) 2011; 37 Christensson, Ekberg, Grubb, Ekberg, Lindström, Lilja (B56) 2003; 94 Shlipak, Sarnak, Katz, Fried, Seliger, Newman, Siscovick, Stehman-Breen (B22) 2005; 352 Tenstad, Roald, Grubb, Aukland (B49) 1996; 56 Markos, Schaepe, Teaford, Rule, Kashani, Lieske, Barreto (B32) 2020; 15 Lepist, Zhang, Hao, Huang, Kosaka, Birkus, Murray, Bannister, Cihlar, Huang, Ray (B42) 2014; 86 Potok, Katz, Bansal, Siscovick, Odden, Ix, Shlipak, Rifkin (B40) 2020; 76 Teaford, Barreto, Vollmer, Rule, Barreto (B36) 2020; 8 Reese, Savina, Generaux, Tracey, Humphreys, Kanaoka, Webster, Harmon, Clarke, Polli (B43) 2013; 41 Lees, Welsh, Celis-Morales, Mackay, Lewsey, Gray, Lyall, Cleland, Gill, Jhund, Pell, Sattar, Welsh, Mark (B23) 2019; 25 Foley, Murray, Li, Herzog, McBean, Eggers, Collins (B19) 2005; 16 Soto, Coelho, Rodrigues, Martins, Frade, Lopes, Cunha, Papoila, Devarajan (B48) 2010; 5 Christensen, Haug, Berild, Bjørnholt, Jelsness-Jørgensen (B33) 2020; 20 Teaford, Stevens, Rule, Mara, Kashani, Lieske, O'Horo, Barreto (B38) 2020; 65 White, Akbari, Hussain, Dinh, Filler, Lepage, Knoll (B55) 2005; 16 Curtis, Nichols, Stainsby, Lim, Aylott, Wynne, Clark, Bloch, Maechler, Martin-Carpenter, Raffi, Min (B44) 2014; 15 Knight, Verhave, Spiegelman, Hillege, de Zeeuw, Curhan, de Jong (B10) 2004; 65 Eckfeldt, Karger, Miller, Rynders, Inker (B28) 2015; 139 Shlipak (B2-20250825) 2006; 145 Ku (B52-20250825) 2021; 32 Peralta (B18-20250825) 2011; 305 Inker (B12-20250825) 2012; 367 Sarnak (B3-20250825) 2005; 142 Keith (B21-20250825) 2004; 164 Yap (B46-20250825) 2011; 37 Peralta (B34-20250825) 2011; 22 Lepist (B42-20250825) 2014; 86 Menon (B17-20250825) 2007; 147 Grubb (B4-20250825) 2011; 71 Teaford (B38-20250825) 2020; 65 Potok (B40-20250825) 2020; 76 Curtis (B44-20250825) 2014; 15 Zhou (B53-20250825) 2022; 82 Tummalapalli (B25-20250825) 2020; 51 Tangri (B8-20250825) 2011; 79 Go (B14-20250825) 2004; 351 Karger (B26-20250825) Potok (B41-20250825) 2020; 76 Peralta (B20-20250825) 2006; 17 Grubb (B1-20250825) 1985; 218 Christensen (B33-20250825) 2020; 20 Galsky (B50-20250825) 2011; 12 Manetti (B11-20250825) 2005; 28 Sjöström (B47-20250825) 2004; 62 Levey (B51-20250825) 1990; 38 Risch (B54-20250825) 2001; 23 Foster (B6-20250825) 2017; 70 Inker (B13-20250825) 2021; 385 Shlipak (B24-20250825) 2006; 17 Vinge (B9-20250825) 1999; 59 Peralta (B35-20250825) 2015; 42 Maillard (B57-20250825) 2008; 85 Shlipak (B16-20250825) 2013; 369 Ismail (B29-20250825) 2017; 50 Foley (B19-20250825) 2005; 16 Teaford (B36-20250825) 2020; 8 Knight (B10-20250825) 2004; 65 Liu (B7-20250825) 2016; 68 Christensson (B56-20250825) 2003; 94 Omote (B45-20250825) 2018; 8 Eckfeldt (B28-20250825) 2015; 139 Shlipak (B22-20250825) 2005; 352 Tenstad (B49-20250825) 1996; 56 Soto (B48-20250825) 2010; 5 Bargnoux (B27-20250825) 2017; 63 Markos (B32-20250825) 2020; 15 Frazee (B37-20250825) 2017; 69 Reese (B43-20250825) 2013; 41 Chen (B39-20250825) 2022; 5 Stevens (B5-20250825) 2009; 75 Menon (B15-20250825) 2008; 73 White (B55-20250825) 2005; 16 Lees (B23-20250825) 2019; 25 |
| References_xml | – volume: 352 start-page: 2049 year: 2005 end-page: 2060 ident: B22 article-title: Cystatin C and the risk of death and cardiovascular events among elderly persons publication-title: N Engl J Med – volume: 164 start-page: 659 year: 2004 end-page: 663 ident: B21 article-title: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization publication-title: Arch Intern Med – volume: 37 start-page: 155 year: 2011 end-page: 157 ident: B46 article-title: Serum cystatin C versus serum creatinine in the estimation of glomerular filtration rate in rhabdomyolysis publication-title: J Ren Care – volume: 76 start-page: 765 year: 2020 end-page: 774 ident: B41 article-title: The difference between cystatin C- and creatinine-based estimated GFR and associations with frailty and adverse outcomes: A cohort analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) publication-title: Am J Kidney Dis – reference: Centers for Medicare and Medicaid Services : Local Coverage Determination: Cystatin C Measurement. LCD ID: L37561. Available at: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=37561&DocType=2. Accessed February 22, 2022 – volume: 50 start-page: 380 year: 2017 end-page: 384 ident: B29 article-title: Improving the translation of novel biomarkers to clinical practice: The story of cystatin C implementation in Canada: A professional practice column publication-title: Clin Biochem – volume: 71 start-page: 145 year: 2011 end-page: 149 ident: B4 article-title: Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation publication-title: Scand J Clin Lab Invest – volume: 73 start-page: 1310 year: 2008 end-page: 1315 ident: B15 article-title: Long-term outcomes in nondiabetic chronic kidney disease publication-title: Kidney Int – volume: 86 start-page: 350 year: 2014 end-page: 357 ident: B42 article-title: Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat publication-title: Kidney Int – volume: 15 start-page: 199 year: 2014 end-page: 208 ident: B44 article-title: Dolutegravir: Clinical and laboratory safety in integrase inhibitor-naive patients publication-title: HIV Clin Trials – volume: 369 start-page: 932 year: 2013 end-page: 943 ident: B16 article-title: Cystatin C versus creatinine in determining risk based on kidney function publication-title: N Engl J Med – reference: Centers for Medicare and Medicaid Services : Clinical Laboratory Fee Schedule Files, file CLAB2022Q1. Available at: https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/22clabq1. Accessed February 22, 2022 – volume: 305 start-page: 1545 year: 2011 end-page: 1552 ident: B18 article-title: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality publication-title: JAMA – volume: 42 start-page: 141 year: 2015 end-page: 147 ident: B35 article-title: A risk score to guide cystatin C testing to detect occult-reduced estimated glomerular filtration rate publication-title: Am J Nephrol – volume: 5 start-page: e2148940 year: 2022 ident: B39 article-title: Association of intraindividual difference in estimated glomerular filtration rate by creatinine vs cystatin C and end-stage kidney disease and mortality publication-title: JAMA Netw Open – volume: 68 start-page: 892 year: 2016 end-page: 900 ident: B7 article-title: Non-GFR determinants of low-molecular-weight serum protein filtration markers in CKD publication-title: Am J Kidney Dis – volume: 8 start-page: 9237 year: 2018 ident: B45 article-title: Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1 publication-title: Sci Rep – volume: 16 start-page: 489 year: 2005 end-page: 495 ident: B19 article-title: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999 publication-title: J Am Soc Nephrol – volume: 62 start-page: 241 year: 2004 end-page: 242 ident: B47 article-title: The shorter T1/2 of cystatin C explains the earlier change of its serum level compared to serum creatinine publication-title: Clin Nephrol – volume: 41 start-page: 353 year: 2013 end-page: 361 ident: B43 article-title: In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor publication-title: Drug Metab Dispos – volume: 75 start-page: 652 year: 2009 end-page: 660 ident: B5 article-title: Factors other than glomerular filtration rate affect serum cystatin C levels publication-title: Kidney Int – volume: 15 start-page: e0243618 year: 2020 ident: B32 article-title: Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic publication-title: PLoS One – volume: 65 start-page: 1416 year: 2004 end-page: 1421 ident: B10 article-title: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement publication-title: Kidney Int – volume: 56 start-page: 409 year: 1996 end-page: 414 ident: B49 article-title: Renal handling of radiolabelled human cystatin C in the rat publication-title: Scand J Clin Lab Invest – volume: 23 start-page: 439 year: 2001 end-page: 448 ident: B54 article-title: Assessment of renal function in renal transplant patients using cystatin C. A comparison to other renal function markers and estimates publication-title: Ren Fail – volume: 22 start-page: 147 year: 2011 end-page: 155 ident: B34 article-title: Cystatin C identifies chronic kidney disease patients at higher risk for complications publication-title: J Am Soc Nephrol – volume: 20 start-page: 515 year: 2020 ident: B33 article-title: Hospital physicians' experiences with procalcitonin-Implications for antimicrobial stewardship; A qualitative study publication-title: BMC Infect Dis – volume: 142 start-page: 497 year: 2005 end-page: 505 ident: B3 article-title: Cystatin C concentration as a risk factor for heart failure in older adults publication-title: Ann Intern Med – volume: 70 start-page: 406 year: 2017 end-page: 414 ident: B6 article-title: Non-GFR determinants of low-molecular-weight serum protein filtration markers in the elderly: AGES-Kidney and MESA-Kidney publication-title: Am J Kidney Dis – volume: 28 start-page: 346 year: 2005 end-page: 349 ident: B11 article-title: Thyroid function differently affects serum cystatin C and creatinine concentrations publication-title: J Endocrinol Invest – volume: 16 start-page: 3763 year: 2005 end-page: 3770 ident: B55 article-title: Estimating glomerular filtration rate in kidney transplantation: A comparison between serum creatinine and cystatin C-based methods publication-title: J Am Soc Nephrol – volume: 85 start-page: 1855 year: 2008 end-page: 1858 ident: B57 article-title: Cystatin C-based equations in renal transplantation: Moving toward a better glomerular filtration rate prediction? publication-title: Transplantation – volume: 63 start-page: 833 year: 2017 end-page: 841 ident: B27 article-title: Multicenter evaluation of cystatin C measurement after assay standardization publication-title: Clin Chem – volume: 51 start-page: 959 year: 2020 end-page: 965 ident: B25 article-title: Availability and affordability of kidney health laboratory tests around the globe publication-title: Am J Nephrol – volume: 145 start-page: 237 year: 2006 end-page: 246 ident: B2 article-title: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease publication-title: Ann Intern Med – volume: 69 start-page: 658 year: 2017 end-page: 666 ident: B37 article-title: Cystatin C-guided vancomycin dosing in critically ill patients: A quality improvement project publication-title: Am J Kidney Dis – volume: 5 start-page: 1745 year: 2010 end-page: 1754 ident: B48 article-title: Cystatin C as a marker of acute kidney injury in the emergency department publication-title: Clin J Am Soc Nephrol – volume: 385 start-page: 1737 year: 2021 end-page: 1749 ident: B13 article-title: New creatinine- and cystatin C-based equations to estimate GFR without race publication-title: N Engl J Med – volume: 82 start-page: 1 year: 2022 end-page: 5 ident: B53 article-title: The value of cystatin C in predicting perioperative and long-term prognosis of renal transplantation publication-title: Scand J Clin Lab Invest – volume: 367 start-page: 20 year: 2012 end-page: 29 ident: B12 article-title: Estimating glomerular filtration rate from serum creatinine and cystatin C publication-title: N Engl J Med – volume: 139 start-page: 888 year: 2015 end-page: 893 ident: B28 article-title: Performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2014 CYS survey publication-title: Arch Pathol Lab Med – volume: 218 start-page: 499 year: 1985 end-page: 503 ident: B1 article-title: Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate publication-title: Acta Med Scand – volume: 8 start-page: 35 year: 2020 ident: B36 article-title: Cystatin C: A primer for pharmacists publication-title: Pharmacy (Basel) – volume: 94 start-page: 19 year: 2003 end-page: 27 ident: B56 article-title: Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation publication-title: Nephron, Physiol – ident: B26 article-title: Improved performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists' 2019 CYS survey publication-title: Arch Pathol Lab Med – volume: 351 start-page: 1296 year: 2004 end-page: 1305 ident: B14 article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization publication-title: N Engl J Med – volume: 12 start-page: 211 year: 2011 end-page: 214 ident: B50 article-title: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy publication-title: Lancet Oncol – volume: 17 start-page: 254 year: 2006 end-page: 261 ident: B24 article-title: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study publication-title: J Am Soc Nephrol – volume: 147 start-page: 19 year: 2007 end-page: 27 ident: B17 article-title: Cystatin C as a risk factor for outcomes in chronic kidney disease publication-title: Ann Intern Med – volume: 25 start-page: 1753 year: 2019 end-page: 1760 ident: B23 article-title: Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease publication-title: Nat Med – volume: 65 start-page: e01487-20 year: 2020 ident: B38 article-title: Prediction of vancomycin levels using cystatin C in overweight and obese patients: A retrospective cohort study of hospitalized patients publication-title: Antimicrob Agents Chemother – volume: 79 start-page: 471 year: 2011 end-page: 477 ident: B8 article-title: Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate publication-title: Kidney Int – volume: 76 start-page: 896 year: 2020 end-page: 898 ident: B40 article-title: The difference between cystatin C- and creatinine-based estimated GFR and incident frailty: An analysis of the Cardiovascular Health Study (CHS) publication-title: Am J Kidney Dis – volume: 17 start-page: 2892 year: 2006 end-page: 2899 ident: B20 article-title: Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease publication-title: J Am Soc Nephrol – volume: 32 start-page: 677 year: 2021 end-page: 685 ident: B52 article-title: Racial disparities in eligibility for preemptive waitlisting for kidney transplantation and modification of eGFR thresholds to equalize waitlist time publication-title: J Am Soc Nephrol – volume: 59 start-page: 587 year: 1999 end-page: 592 ident: B9 article-title: Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults publication-title: Scand J Clin Lab Invest – volume: 38 start-page: 167 year: 1990 end-page: 184 ident: B51 article-title: Measurement of renal function in chronic renal disease publication-title: Kidney Int – volume: 22 start-page: 147 year: 2011 ident: B34-20250825 article-title: Cystatin C identifies chronic kidney disease patients at higher risk for complications publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2010050483 – volume: 65 start-page: 1416 year: 2004 ident: B10-20250825 article-title: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement publication-title: Kidney Int doi: 10.1111/j.1523-1755.2004.00517.x – volume: 28 start-page: 346 year: 2005 ident: B11-20250825 article-title: Thyroid function differently affects serum cystatin C and creatinine concentrations publication-title: J Endocrinol Invest doi: 10.1007/BF03347201 – volume: 8 start-page: 9237 year: 2018 ident: B45-20250825 article-title: Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1 publication-title: Sci Rep doi: 10.1038/s41598-018-27672-y – volume: 85 start-page: 1855 year: 2008 ident: B57-20250825 article-title: Cystatin C-based equations in renal transplantation: Moving toward a better glomerular filtration rate prediction? publication-title: Transplantation doi: 10.1097/TP.0b013e3181744225 – volume: 76 start-page: 765 year: 2020 ident: B41-20250825 article-title: The difference between cystatin C- and creatinine-based estimated GFR and associations with frailty and adverse outcomes: A cohort analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2020.05.017 – volume: 62 start-page: 241 year: 2004 ident: B47-20250825 article-title: The shorter T1/2 of cystatin C explains the earlier change of its serum level compared to serum creatinine publication-title: Clin Nephrol doi: 10.5414/CNP62241 – volume: 71 start-page: 145 year: 2011 ident: B4-20250825 article-title: Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation publication-title: Scand J Clin Lab Invest doi: 10.3109/00365513.2010.546879 – volume: 17 start-page: 254 year: 2006 ident: B24-20250825 article-title: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2005050545 – ident: B26-20250825 article-title: Improved performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists’ 2019 CYS survey publication-title: Arch Pathol Lab Med – volume: 369 start-page: 932 year: 2013 ident: B16-20250825 article-title: Cystatin C versus creatinine in determining risk based on kidney function publication-title: N Engl J Med doi: 10.1056/NEJMoa1214234 – volume: 352 start-page: 2049 year: 2005 ident: B22-20250825 article-title: Cystatin C and the risk of death and cardiovascular events among elderly persons publication-title: N Engl J Med doi: 10.1056/NEJMoa043161 – volume: 65 start-page: e01487-20 year: 2020 ident: B38-20250825 article-title: Prediction of vancomycin levels using cystatin C in overweight and obese patients: A retrospective cohort study of hospitalized patients publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01487-20 – volume: 12 start-page: 211 year: 2011 ident: B50-20250825 article-title: A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70275-8 – volume: 218 start-page: 499 year: 1985 ident: B1-20250825 article-title: Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate publication-title: Acta Med Scand doi: 10.1111/j.0954-6820.1985.tb08880.x – volume: 145 start-page: 237 year: 2006 ident: B2-20250825 article-title: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease publication-title: Ann Intern Med doi: 10.7326/0003-4819-145-4-200608150-00003 – volume: 70 start-page: 406 year: 2017 ident: B6-20250825 article-title: Non-GFR determinants of low-molecular-weight serum protein filtration markers in the elderly: AGES-Kidney and MESA-Kidney publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2017.03.021 – volume: 75 start-page: 652 year: 2009 ident: B5-20250825 article-title: Factors other than glomerular filtration rate affect serum cystatin C levels publication-title: Kidney Int doi: 10.1038/ki.2008.638 – volume: 68 start-page: 892 year: 2016 ident: B7-20250825 article-title: Non-GFR determinants of low-molecular-weight serum protein filtration markers in CKD publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2016.07.021 – volume: 42 start-page: 141 year: 2015 ident: B35-20250825 article-title: A risk score to guide cystatin C testing to detect occult-reduced estimated glomerular filtration rate publication-title: Am J Nephrol doi: 10.1159/000439231 – volume: 8 start-page: 35 year: 2020 ident: B36-20250825 article-title: Cystatin C: A primer for pharmacists publication-title: Pharmacy (Basel) doi: 10.3390/pharmacy8010035 – volume: 20 start-page: 515 year: 2020 ident: B33-20250825 article-title: Hospital physicians’ experiences with procalcitonin—Implications for antimicrobial stewardship; A qualitative study publication-title: BMC Infect Dis doi: 10.1186/s12879-020-05246-6 – volume: 59 start-page: 587 year: 1999 ident: B9-20250825 article-title: Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults publication-title: Scand J Clin Lab Invest doi: 10.1080/00365519950185076 – volume: 23 start-page: 439 year: 2001 ident: B54-20250825 article-title: Assessment of renal function in renal transplant patients using cystatin C. A comparison to other renal function markers and estimates publication-title: Ren Fail doi: 10.1081/JDI-100104727 – volume: 94 start-page: 19 year: 2003 ident: B56-20250825 article-title: Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation publication-title: Nephron, Physiol doi: 10.1159/000071287 – volume: 164 start-page: 659 year: 2004 ident: B21-20250825 article-title: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization publication-title: Arch Intern Med doi: 10.1001/archinte.164.6.659 – volume: 76 start-page: 896 year: 2020 ident: B40-20250825 article-title: The difference between cystatin C- and creatinine-based estimated GFR and incident frailty: An analysis of the Cardiovascular Health Study (CHS) publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2020.05.018 – volume: 15 start-page: e0243618 year: 2020 ident: B32-20250825 article-title: Clinician perspectives on inpatient cystatin C utilization: A qualitative case study at Mayo Clinic publication-title: PLoS One doi: 10.1371/journal.pone.0243618 – volume: 16 start-page: 489 year: 2005 ident: B19-20250825 article-title: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2004030203 – volume: 17 start-page: 2892 year: 2006 ident: B20-20250825 article-title: Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2005101122 – volume: 69 start-page: 658 year: 2017 ident: B37-20250825 article-title: Cystatin C-guided vancomycin dosing in critically ill patients: A quality improvement project publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2016.11.016 – volume: 32 start-page: 677 year: 2021 ident: B52-20250825 article-title: Racial disparities in eligibility for preemptive waitlisting for kidney transplantation and modification of eGFR thresholds to equalize waitlist time publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2020081144 – volume: 5 start-page: e2148940 year: 2022 ident: B39-20250825 article-title: Association of intraindividual difference in estimated glomerular filtration rate by creatinine vs cystatin C and end-stage kidney disease and mortality publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.48940 – volume: 305 start-page: 1545 year: 2011 ident: B18-20250825 article-title: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality publication-title: JAMA doi: 10.1001/jama.2011.468 – volume: 51 start-page: 959 year: 2020 ident: B25-20250825 article-title: Availability and affordability of kidney health laboratory tests around the globe publication-title: Am J Nephrol doi: 10.1159/000511848 – volume: 73 start-page: 1310 year: 2008 ident: B15-20250825 article-title: Long-term outcomes in nondiabetic chronic kidney disease publication-title: Kidney Int doi: 10.1038/ki.2008.67 – volume: 50 start-page: 380 year: 2017 ident: B29-20250825 article-title: Improving the translation of novel biomarkers to clinical practice: The story of cystatin C implementation in Canada: A professional practice column publication-title: Clin Biochem doi: 10.1016/j.clinbiochem.2017.01.005 – volume: 142 start-page: 497 year: 2005 ident: B3-20250825 article-title: Cystatin C concentration as a risk factor for heart failure in older adults publication-title: Ann Intern Med doi: 10.7326/0003-4819-142-7-200504050-00008 – volume: 351 start-page: 1296 year: 2004 ident: B14-20250825 article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization publication-title: N Engl J Med doi: 10.1056/NEJMoa041031 – volume: 63 start-page: 833 year: 2017 ident: B27-20250825 article-title: Multicenter evaluation of cystatin C measurement after assay standardization publication-title: Clin Chem doi: 10.1373/clinchem.2016.264325 – volume: 385 start-page: 1737 year: 2021 ident: B13-20250825 article-title: New creatinine- and cystatin C-based equations to estimate GFR without race publication-title: N Engl J Med doi: 10.1056/NEJMoa2102953 – volume: 41 start-page: 353 year: 2013 ident: B43-20250825 article-title: In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor publication-title: Drug Metab Dispos doi: 10.1124/dmd.112.048918 – volume: 147 start-page: 19 year: 2007 ident: B17-20250825 article-title: Cystatin C as a risk factor for outcomes in chronic kidney disease publication-title: Ann Intern Med doi: 10.7326/0003-4819-147-1-200707030-00004 – volume: 25 start-page: 1753 year: 2019 ident: B23-20250825 article-title: Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease publication-title: Nat Med doi: 10.1038/s41591-019-0627-8 – volume: 79 start-page: 471 year: 2011 ident: B8-20250825 article-title: Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate publication-title: Kidney Int doi: 10.1038/ki.2010.431 – volume: 367 start-page: 20 year: 2012 ident: B12-20250825 article-title: Estimating glomerular filtration rate from serum creatinine and cystatin C publication-title: N Engl J Med doi: 10.1056/NEJMoa1114248 – volume: 5 start-page: 1745 year: 2010 ident: B48-20250825 article-title: Cystatin C as a marker of acute kidney injury in the emergency department publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.00690110 – volume: 38 start-page: 167 year: 1990 ident: B51-20250825 article-title: Measurement of renal function in chronic renal disease publication-title: Kidney Int doi: 10.1038/ki.1990.182 – volume: 82 start-page: 1 year: 2022 ident: B53-20250825 article-title: The value of cystatin C in predicting perioperative and long-term prognosis of renal transplantation publication-title: Scand J Clin Lab Invest doi: 10.1080/00365513.2021.1989714 – volume: 86 start-page: 350 year: 2014 ident: B42-20250825 article-title: Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat publication-title: Kidney Int doi: 10.1038/ki.2014.66 – volume: 15 start-page: 199 year: 2014 ident: B44-20250825 article-title: Dolutegravir: Clinical and laboratory safety in integrase inhibitor-naive patients publication-title: HIV Clin Trials doi: 10.1310/hct1505-199 – volume: 56 start-page: 409 year: 1996 ident: B49-20250825 article-title: Renal handling of radiolabelled human cystatin C in the rat publication-title: Scand J Clin Lab Invest doi: 10.3109/00365519609088795 – volume: 16 start-page: 3763 year: 2005 ident: B55-20250825 article-title: Estimating glomerular filtration rate in kidney transplantation: A comparison between serum creatinine and cystatin C-based methods publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2005050512 – volume: 139 start-page: 888 year: 2015 ident: B28-20250825 article-title: Performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2014 CYS survey publication-title: Arch Pathol Lab Med doi: 10.5858/arpa.2014-0427-CP – volume: 37 start-page: 155 year: 2011 ident: B46-20250825 article-title: Serum cystatin C versus serum creatinine in the estimation of glomerular filtration rate in rhabdomyolysis publication-title: J Ren Care doi: 10.1111/j.1755-6686.2011.00228.x |
| SSID | ssj0002922836 |
| Score | 2.5185678 |
| SecondaryResourceType | review_article |
| Snippet | Cystatin C has been shown to be a reliable and accurate marker of kidney function across diverse populations. The 2012 Kidney Disease Improving Global Outcomes... |
| SourceID | pubmedcentral proquest pubmed crossref wolterskluwer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1807 |
| SubjectTerms | Creatinine Cystatin C Glomerular Filtration Rate Humans Kidney Function Tests Renal Insufficiency, Chronic - diagnosis Review |
| Title | Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.34067/KID.0003202022 https://www.ncbi.nlm.nih.gov/pubmed/36514729 https://www.proquest.com/docview/2754504489 https://pubmed.ncbi.nlm.nih.gov/PMC9717651 |
| Volume | 3 |
| WOSCitedRecordID | wos000876642000024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2641-7650 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002922836 issn: 2641-7650 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2641-7650 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002922836 issn: 2641-7650 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6FwgEJIRCv8IgWiQNS4lBn_dg9Vm4qUEmpUEG5WX6sVYtgV7Vb2gt_gD_NzK7XD0olQOISRbazsXc-z87szHxDyCtfJMyJeAYvUupbAApmRbDSWjJ20pTHdiwU2fPn9_7BAV-vxeFo9MPUwpxv_KLgFxfi5L-KGo6BsLF09i_E3Q4KB-A7CB0-Qezw-UeCV32Sa1ATlfa5vzYs3JVJ1AxMMaRp1tnlk-sEguASy4ywHBAt0yUoATBrAU17H_um7H6eFvKSeW28IzhuVVicy2kwb9VuWZdK6X6YT3c2mL7UhnnyrGkHtiuLdoFYYgELwNOk9WNsYbqa9zcowLcFza7r_Xs1AaismjRU3AmRgNQubCCVvgPTzLZ8T_PQGuXM-hjc7mlam-tuuc2qDYaK87sVgYHBgkHp_Xe7SFWJ3eK3dSH0LzTbh6tAgGvrYTn-zYXvClSRq-_dht1CIFOQp-mh1LBvhoMOLZsr7srVrNs730rMiKi-qIKInllzdI_cbfwRuqNxdJ-MZPGArDsMzWgPQTMK-KEGP3SIH5oXVOGHGvzQgNYlNfihgJ-H5NPe8ih4azUtOKzEheeyvCQSXGbIYBQ5aF6KLJGcyTh1I9uNuROBvekmYJV74Lrzhc0yP03cOIm4u3B5xh6RraIs5BNCUzjjYJw9s1NHkRDZkcdsL_NlmqWuOyZzM31h0jwXtknZhOCnqvkOYb7Dbr7H5HX7gxNNzXL9pS-NPEJQnxgTiwpZnlUhSBpuxnG4GJPHWj7tYAzA4IDzOSb-QHLtBUjNPjxT5MeKor2B0pjMBjIOdXHzdbf59J__6Bm53b16z8lWfXomX5BbyXmdV6cTcsNf84nabpooUP8EbZTFeg |
| linkProvider | ISSN International Centre |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advantages%2C+Limitations%2C+and+Clinical+Considerations+in+Using+Cystatin+C+to+Estimate+GFR&rft.jtitle=Kidney360&rft.au=Chen%2C+Debbie+C.&rft.au=Potok%2C+O.+Alison&rft.au=Rifkin%2C+Dena&rft.au=Estrella%2C+Michelle+M.&rft.date=2022-10-27&rft.pub=American+Society+of+Nephrology&rft.eissn=2641-7650&rft.volume=3&rft.issue=10&rft.spage=1807&rft.epage=1814&rft_id=info:doi/10.34067%2FKID.0003202022&rft.externalDocID=PMC9717651 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2641-7650&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2641-7650&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2641-7650&client=summon |